CSRXP: PRESIDENT SHOULD FOCUS ON HOLDING BIG PHARMA ACCOUNTABLE TO LOWER RX PRICES, ABANDON REBATE RULE

Tweet Misstates Impact of Misguided Rebate Rule That Would Do Nothing to Lower Drug Prices, While Increasing Medicare Premiums

For Immediate Release
Contact: Jon Conradi
860-235-3884
[email protected]

Washington, D.C. – The Campaign for Sustainable Rx Pricing (CSRxP) issued a statement Sunday in response to tweet chain from the president announcing he signed an executive order tying drug prices to those paid in other countries and pointing to the administration’s reboot of a plan to eliminate drug rebates in Medicare Part D.

“The president should focus on holding Big Pharma accountable to lower prescription drug prices and abandon the Pharma-backed Rebate Rule,” said CSRxP executive director Lauren Aronson. “Despite recent claims from the president, the administration’s own actuaries say the Rebate Rule would do nothing to lower drug prices but would increase premiums on Medicare Part D beneficiaries, cost taxpayers more than $200 billion and hand Big Pharma a more than $100 billion bailout.”

Get The Facts on the Rebate Rule

The Rebate Rule undermines the president’s drug pricing agenda and a plurality of Americans oppose the Rule’s implementation:

If implemented, the Rebate Rule would:
Learn more about the misguided Rebate Rule HERE.
Learn more about market-based solutions to hold Big Pharma accountable and lower prescription drug prices HERE.

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.